SLC5A2 and type 2 diabetes mellitus: As sodium-glucose cotransporter-2 inhibitors (SGLT2i) demonstrate significant cardiovascular benefits in T2D patients across multiple cardiovascular outcome trials [2–7], current guidelines including the latest one by the American Diabetes Association (ADA) recommend the use of SGLT2i in T2D patients with established or at high risk of CVD independent of glycaemic control, regardless of baseline metformin use [8–11].